Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tailoring an antihyperglycaemic regimen to a monogenic diabetes variant.

BMJ case reports - 20 Sept 2024

Nemiroff Samuel, Goulden Peter

Abstract excerpt

Monogenic diabetes mellitus (MDM) is an under-recognised entity that can be effectively treated with personalised therapies tailored to specific variants. Current guidelines suggest considering MDM in antibody-negative, C peptide-retaining patients with impaired glucose metabolism, particularly those with a significant family history and healthy body mass index. Here, we present a case of a patient with an MDM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Diabetes Mellitus
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Phenotype

Source

Identifiers

PMID: 39306338
DOI: 10.1136/bcr-2024-260703

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Tailoring an antihyperglycaemic regimen to a monogenic diabetes variant.PMID 39306338Read ↗

Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?Semantic proximity Read ↗

Clinical, glycometric features and treatment in a family with monogenic diabetes due to a new mutation in the insulin gene.Semantic proximity Read ↗

Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapySemantic proximity Read ↗

CRISIS HIPERGLICÉMICA AGUDA COMO DEBUT DE DIABETES MELLITUS Y COVID-19: ¿UNA NUEVA CAUSA DE DIABETES?Semantic proximity Read ↗

Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia.Semantic proximity Read ↗

Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.Semantic proximity Read ↗

Our evolving understanding of monogenic diabetes: possibilities of improving glycaemic control following transfer from insulin to sulphonylureas.Semantic proximity Read ↗

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor AgonistsSemantic proximity Read ↗

Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.